Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Carotid Decision Making

12 novembre 2026 mis à jour par: Jesse.A.Columbo, Dartmouth-Hitchcock Medical Center

Improving Shared Decision Making for Older Patients With Carotid Artery Stenosis

Carotid artery stenosis is a common cause of ischemic stroke in the U.S. and disproportionately affects older adults. Patients with carotid artery stenosis face a complex set of decisions when choosing a treatment strategy. Patients must choose among surveillance with medical therapy alone, versus medical therapy plus one of three different procedures. Each treatment option has different levels of evidence to support it, some of which are decades old. Each procedural option has different expected periprocedural courses, different recoveries, and different cardiovascular risks. This challenging decision is amplified among older adults, where decisional values are often different from younger patients traditionally studied in randomized or observational studies. A decision aid could assist patients and providers who are navigating this decision, but no decision aid currently exists that includes all the contemporary carotid artery stenosis treatment options. In addition, as of October 2023, participation in a shared decision-making conversation is a Medicare-mandated component of carotid stenosis care, with reimbursement for procedures predicated on the documentation of the conversation with the patient.

The objective of this project is to conduct a single arm open label trial to test the feasibility of using a paper-based decision aid for patients considering carotid revascularization. The investigators will conduct a feasibility trial using the decision aid on older adults who are considering carotid revascularization. The investigators will recruit 50 participants aged 65 or older from the vascular surgery clinic and administer the decision aid. The investigators will purposively sample at least 10 participants that are age 80 or older. Primary outcomes will center on feasibility, and secondary outcomes will center on decisional conflict and regret.

Aperçu de l'étude

Statut

Pas encore de recrutement

Intervention / Traitement

Description détaillée

The primary outcomes of this single arm open label feasibility trial are focused on feasibility, and the secondary outcomes will provide data to inform a subsequent R01 study design.

Exposure: The decision aid

Setting: The investigators will sample newly referred and longitudinally treated patients from the Dartmouth Health Vascular Clinic who are being treated for carotid artery stenosis and who are considering carotid revascularization.

Sampling strategy: The investigators will enroll 50 patient-participants. The investigators will review the clinic schedules of the 18 providers each day in clinic and screen them for patients being seen for carotid artery stenosis. The investigators will then discuss with the providers in clinic that day whether any of the patients they are seeing may be considered for carotid revascularization and whether that respective patient would be appropriate for and have the capacity to utilize a decision aid. The investigators will purposively sample a minimum of 10 participants who are aged 80 and older to ensure adequate representation of this age group. Patients with carotid stenosis routinely have a high burden of comorbidities including hypertension, diabetes, coronary disease, kidney disease, and smoking. Patients treated in the Dartmouth Vascular Clinic are representative of this population and will allow us to sample a cohort with multiple comorbidities. Patients meeting the inclusion and exclusion criteria and felt to be appropriate for a decision aid per their treating provider will be approached in clinic to discuss the study.

Statistical analysis:

Outcome 1: The investigators will measure the mean and standard deviation of the time of the clinic visit. The investigators will calculate the visit time from the time of patient check in until the completion of the clinic visit, as assessed by a direct observer. The investigators will compare this to baseline time measurements recorded in the electronic health record for a random sample of 50 carotid stenosis patients meeting the same inclusion / exclusion criteria in the past 3 months.

Outcome 2: The investigators will conduct semi-structured interviews with 10 patients to follow up on the findings from the surveys above. These will be semi-structured interviews that are designed to assess whether the tradeoffs for each decision aid option were understood, and whether they felt that the decision aid helped them reach their choice. The interviews will be recorded and transcribed. The constant comparative method will be used to identify codes inductively. Two independent coders will analyze the data, and then codes will be discussed and data organized. Areas of disagreement will be resolved by consensus, or, if consensus is not possible, by a third independent reviewer. The investigators will organize the codes into key domains through data reduction and interpretation, paying particular attention to the frequency of specific ideas / codes mentioned by participants, and how many participants mentioned them.

The investigators will administer a similar survey to their treating providers within 1 week of the clinic visit. The results of the Likert surveys will be converted to a 5-point scale and the mean and median response will be computed with 95% confidence intervals. The investigators will additionally conduct semi-structured interviews with treating providers to determine feasibility of decision aid use in routine practice.

Secondary outcomes: The investigators will administer a validated decisional conflict scale and decisional regret scale before and after administration of the decision aid. The investigators will use the low literacy version to account for the high prevalence of low literacy in older adults. The investigators will analyze the results according to the validated methods for that survey and compare the before and after results. The investigators will additionally measure the actual treatment decision made by the patient and report this unadjusted. The investigators will finally measure knowledge-based questions that will be administered before and after patients are given the decision aid.

Sample size considerations: For outcome 1, given a sample size of 50 normally distributed outcomes, this will result in sample size with 95% confidence intervals with half widths of 0.32 standard deviation of the matched visit estimates of added time for increasing to 0.34, and 0.36 with 10% and 20% missing data. Similar results hold for the Likert survey in Outcome 3.

Potential pitfalls and alternative strategies: It is possible that it may not be known whether a patient would benefit from a decision aid until the patient receives an imaging study demonstrating the severity of the patient's carotid disease, which may occur just before the patient's clinic visit. Therefore, for patients who are scheduled for a clinic visit but do not have an imaging study, the investigators will ask the vascular laboratory (where the studies are conducted) to notify study personnel once the imaging study is completed.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • New Hampshire
      • Lebanon, New Hampshire, États-Unis, 03766
        • Dartmouth Hitchcock Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

65 ans et plus (Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patients seen in the outpatient clinic who are considering carotid revascularization versus medical therapy or who were admitted to the hospital and are considering elective carotid revascularization.

Exclusion Criteria:

  • Patients who are considering urgent revascularization, those unable to provide informed consent using the Short Portable Mental Status Questionnaire or those unable to participate in follow-up interview or survey scales due to cognitive reasons.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Decision aid feasibility

Single arm pilot feasibility study of using a decision aid for patients with asymptomatic carotid artery stenosis considering revascularization

The decision aid is paper-based and includes pie charts of perioperative risks and incorporates patient values and preferences about autonomy of decision making.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Time to administer the decision aid
Délai: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Defined as time from clinic check-in until completion of the visit

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Understanding of the decision aid
Délai: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured by a knowledge survey

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Decisional conflict
Délai: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured using the validated decisional conflict scale

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Decisional regret
Délai: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured using the validated decisional regret scale

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Actual treatment decision made
Délai: Assessed for up to 8 weeks

What treatment the patient actually decided on

Assessed for up to 8 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 novembre 2026

Achèvement primaire (Estimé)

15 mai 2028

Achèvement de l'étude (Estimé)

15 mai 2028

Dates d'inscription aux études

Première soumission

2 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Will not share individual patient data due to confidentiality.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner